COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE ® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging ...

You don’t need to be Willy Wonka or own a chocolate factory to make your own candy bars. It might sound intimidating, but chocolate bars are actually simple to make. Plus, doing it yourself gives you ...

FARMINGTON HILLS, MICH (WXYZ) — Think Sweet is a vibrant, modern confectionery and café located in Farmington Hills, 32902 Middlebelt Road. Operating under the ...

A potential cure for type 1 diabetes has been identified by scientists in a new mouse study. In an animal study, researchers at Stanford School of Medicine discovered that resetting the immune system ...

Discover how to turn creative ideas into stunning visuals with invideo AI, followed by a detailed step-by-step tutorial on making your own combination lock from metal. This video explores both the ...

Interim results from the phase 2 NESCIO trial suggest combination neoadjuvant immunotherapy has efficacy in locally advanced clear cell renal cell carcinoma. Neoadjuvant combinations of ipilimumab or ...

The FDA approved lurbinectedin (Zepzelca) plus either atezolizumab (Tecentriq) or atezolizumab and hyaluronidase (Tecentriq Hybreza) as first-line maintenance therapy for extensive-stage small cell ...

An FDA approval is setting a new benchmark for future treatment for first-line small cell lung cancer. The FDA has greenlighted Jazz Pharmaceuticals’ Zepzelca, used in combination with Roche’s ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the combination of lurbinectedin and atezolizumab as first-line maintenance treatment for ...

An observational study was conducted across three Spanish hospitals to compare two glucocorticoid regimens in treating 151 patients newly diagnosed with giant cell arteritis (mean age, 74.6 years; 71% ...

A total of 105 HLA-A2 positive patients enrolled in the Combi-TED study, which explores the combination of Tedopi® with either an anti-PD1 checkpoint inhibitor or chemotherapy as a second-line ...